| Metric | Value (₹ Cr) | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue | 1.0K | 7.8% | 13.6% |
| Total Income | 1.2K | 18.9% | 14.2% |
| Expenditure | 906.93 | 8.0% | 11.3% |
| PBT | 264.18 | 166.2% | 25.2% |
| Net Profit | 202.13 | 166.9% | 26.4% |
| OPM | 21.71% | 5.25pp | 2.58pp |
| NPM | 17.26% | 9.57pp | 1.66pp |
| EPS | 9.95 | 166.8% | 26.3% |
Narayana Hrudayalaya FY26 Revenue Up 44% to ₹78,960 Mn
22 May 2026 · 22 May, 10:21 pm
Summary
Narayana Hrudayalaya Limited announced a strong financial performance for Q4 FY26 and the full fiscal year FY26. Consolidated operating revenue for Q4 FY26 surged by 75.8% year-on-year to ₹2,593.8 crore, contributing to an impressive FY26 consolidated revenue of ₹7,896.0 crore, a 44.0% increase from the previous year. Adjusted EBITDA for Q4 FY26 rose by 40.3% to ₹539.4 crore, with a 20.8% margin, while the full year adjusted PAT grew by 18.7% to ₹937.4 crore, achieving an 11.9% margin. The company highlighted robust growth across its India and international operations, particularly noting the significant contribution from its UK segment which became operational in November 2025.
Key Highlights
- 1
Narayana Hrudayalaya Limited reported a significant consolidated operating revenue of ₹2,593.8 crore for Q4 FY26, marking a robust 75.8% year-on-year growth.
- 2
For the full fiscal year FY26, consolidated operating revenue reached ₹7,896.0 crore, demonstrating a substantial 44.0% increase compared to the previous year.
- 3
Adjusted EBITDA for Q4 FY26 grew by 40.3% year-on-year to ₹539.4 crore, maintaining a margin of 20.8%.
- 4
The company achieved an adjusted PAT of ₹937.4 crore for FY26, an 18.7% increase year-on-year, with an adjusted PAT margin of 11.9%.
- 5
India's operating revenue contributed ₹4,797.4 crore to FY26 results, showing a healthy 10.3% year-on-year growth.
- 6
The UK segment, operational from November 6, 2025, contributed ₹1,299.2 crore to FY26 revenue, with Q4 FY26 UK revenue at ₹809.0 crore, up 65% quarter-on-quarter.
- 7
The Group successfully performed over 750 robotic cardiac surgeries in FY26, including 160 TAVIs, showcasing strong clinical volumes and advanced procedural capabilities.
Management Comments
Dr. Emmanuel Rupert
Commenting on the performance, Dr. Emmanuel Rupert, Managing Director and Gro
Informational and educational content only. Not investment advice.